Assessment of human antihuman antibodies to eculizumab after long‐term treatment in patients with paroxysmal nocturnal hemoglobinuria

CARMEN BALDAZZI,* SIMONA LUATTI, STEFANIA PAOLINI, CRISTINA PAPAYANNIDIS, GIULIA MARZOCCHI, GAIA AMELI, GIOVANNI MARTINELLI MICHELE CAVO AND NICOLETTA TESTONI Institute of Hematology and Medical Oncology, “Lorenzo E Ariosto Ser agnoli”, Sant’Orsola-Malpighi Hospital-University of Bologna, Bologna, Italy Additional Supporting Information may be found in the online version of this article. *Correspondence to: Carmen Baldazzi, PhD; Institute of Hematology and Medical Oncology “Lorenzo e Ariosto Seragnoli”, Sant’Orsola-Malpighi Hospital-University, Via Massarenti 9, 40138 Bologna, Italy. E-mail: carmen.baldazzi@gmail.com Received for publication: 7 December 2015; Accepted: 11 December 2015 Published online: 15 December 2015 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ajh.24276

[1]  V. Devanarayan,et al.  Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations , 2014, The AAPS Journal.

[2]  J. Maciejewski,et al.  Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria , 2013, British journal of haematology.

[3]  J. Cowell,et al.  Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities , 2012, Leukemia.

[4]  Christine J. Bryson,et al.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges. , 2010, Self/nonself.

[5]  M. Baccarani,et al.  B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. , 2010, Leukemia research.

[6]  L. Medeiros,et al.  8p11 myeloproliferative syndrome: a review. , 2010, Human pathology.

[7]  A. Tefferi,et al.  Chromosome 8p11.2 translocations: Prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution , 2010, American journal of hematology.

[8]  A. Nechansky.  HAHA--nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. , 2010, Journal of pharmaceutical and biomedical analysis.

[9]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[10]  N. Young,et al.  Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. , 2008, Blood.

[11]  N. Young,et al.  The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. , 2006, The New England journal of medicine.

[12]  J. Foote,et al.  Immunogenicity of engineered antibodies. , 2005, Methods.

[13]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[14]  A. Mire-Sluis,et al.  Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. , 2002, Current pharmaceutical biotechnology.